{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.02","value":"7.61"}]}],"title":"Week 1 (N=271)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.78","value":"8.18"}]}],"title":"Week 48 (N=216)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"292"}],"units":"Participants"}],"description":"The Patient Global Assessment is two questions which assess the overall health-related quality of life (HRQOL) and symptoms of the patient. Each item is answered on a 15-point Likert scale ranging from 'A very great deal worse' (1) to 'A very great deal better' (15). A higher score indicates that quality of life or symptoms have improved.","dispersionType":"Standard Deviation","groups":[{"description":"Romiplostim administered to adult participants subcutaneously weekly at doses up to 30 µg/kg based on platelet counts. After Amendment 1 the maximum weekly dose was reduced to 15 µg/kg, and after Amendment 2 the maximum weekly dose was reduced to 10 µg/kg. However, participants enrolled prior to Amendment 2 who were receiving \\>10 µg/kg were permitted to remain on that higher dose, but could not increase their dose. In addition, if the participant's dose was decreased, it could not be increased to \\>10 µg/kg.","id":"OG000","title":"Romiplostim in Adults"}],"paramType":"MEAN","populationDescription":"Full analysis set with available data. Patient reported outcomes were only analyzed in adult participants.","reportingStatus":"POSTED","timeFrame":"Week 1 and Week 48","title":"Patient Global Assessment","type":"SECONDARY","unitOfMeasure":"scores on a scale"}